Management of Patients with Chronic Hepatitis B and Antiviral Resistance
This answer is incorrect. Although entecavir is more potent than lamivudine (and has a higher barrier to resistance), it has reduced efficacy in patients with pre-existing lamivudine resistance because of partial cross-resistance. Most experts would not view a switch to entecavir as the best option in this setting. In addition, if entecavir is used in patients who have lamivudine resistance, it should be used at the 1.0 mg once daily dose, which is twice the dose given to patients without lamivudine resistance.
Choose another answer: